News

The medicine is said to be the first and only specific interleukin-23 (IL-23) inhibitor approved for treating moderately to severely active CD in adults. The approval follows the

With this FDA approval, IMCIVREE is indicated for chronic weight management in adult and pediatric patients aged six years and older with monogenic or syndromic obesity due to

This agreement will allow Quoin to offer healthcare professionals and patients in greater China, including Hong Kong, Macau and Taiwan, with access to its products following receipt regulatory

A pre-clinical stage biotech company, Trutino Biosciences is engaged in discovering and developing next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases. Boehringer Ingelheim has a two-pronged research

Olumiant is marked as the first and only systemic medicine for severe AA adult patients. It is an oral and once-daily JAK inhibitor which is available through specialty

The collaboration will use ImmunoGen’s linker-payload technology which is directed to new targets that are identified by OBT through its OGAP discovery platform. The two companies will jointly

Under the terms of the deal, Bavarian Nordic will be responsible for the supply of 500,000 additional doses of Jynneos vaccines this year. Previously in 2020, the company

Under the deal, Aurigene will receive $8m of upfront licensing payment for rights to the company’s pre-existing programme. The company will also be eligible for up to $60m

The antibody is indicated to treat R/R FL patients who have received at least two prior systemic therapies. Lunsumio is a CD20xCD3 T-cell engaging bispecific antibody that targets